Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2026)

Crinetics Pharmaceuticals' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 22.42% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 22.42% YoY), while the FY2025 annual figure was $3.8 million, down 19.01% from the prior year.
• Non-Current Deffered Revenue was $3.3 million for Q1 2026 at Crinetics Pharmaceuticals, down from $3.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $7.2 million in Q1 2022 to a low of $3.3 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $5.1 million across 5 years, with a median of $4.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue soared 94928.57% in 2022, then retreated 26.36% in 2023.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $6.1 million in 2022, then fell by 22.14% to $4.8 million in 2023, then declined by 0.97% to $4.7 million in 2024, then fell by 19.01% to $3.8 million in 2025, then slipped by 12.18% to $3.3 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $3.3 million (Q1 2026), $3.8 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.